Isradipine vs Propranolol in Hydrochlorothiazide-Treated Hypertensives

A total of 203 patients with hypertension (supine diastolic blood pressure of 100-119 mm Hg) from six centers entered into a 3-week placebo baseline followed by 5 weeks of active treatment (either placebo or isradipine 2.5, 5, 7.5, or 10 mg BID) to determine the effectiveness of isradipine on blood pressure control. Electrocardiographic criteria for left-ventricular ischemia were coded blindly using the Minnesota Codes 4-1 to 4-4 and 5-1 to 5-3 at the end of baseline and active treatment periods. One hundred seventy patients with hypertension and matching and complete electrocardiograms completed the study for analysis: 63 (37%) were white and 117 (69%) were men. They were 52.1 +/- 10.3 years old mean +/- SD; range: 22-77 years). No myocardial infarction occurred during the active phase. Fifty-eight of 170 (34%) at baseline and 54 of 116 (32%) at week 5 had left atrial enlargement. Romhilt-Estes left-ventricular hypertrophy was not significantly different at baseline versus active treatment: 14 of 170 (8.2%) versus 15 of 170 (8.8%). At baseline, the rate of active ischemia was 28.2% (48/170): 27.8% (10/36) were randomized to receive placebo during active treatment and 28.4% (38/134) were given isradipine (P = NS). For those without ischemia at baseline, the rate of change to electrocardiographic ischemia during active treatment was 0% (0/26) for those receiving placebo and 3.1% (3/96) for those taking isradipine (P = NS). For those with ischemia at baseline, the rate of change to no ischemia during active treatment was 20% (2/10) for those receiving placebo and 10.5% (4/38) for those taking isradipine (P = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers

Weinberger

1991

The American Journal of Medicine

View full text Add to dashboard Cite

Isradipine vs Propranolol in Hydrochlorothiazide-Treated Hypertensives

Cited by 6 publications

References 12 publications

Calcium Channel Blockers as Second-Line Therapy in Thiazide-Resistant Hypertension

Calcium Channel Blockers as Second-Line Therapy in Thiazide-Resistant Hypertension

Assessment of Electrocardiographic Ischemia in Hypertensive Patients Treated with Isradipine or Placebo

The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers

Contact Info

Product

Resources

About